血浆氧化三甲胺浓度与2型糖尿病的关系

doi:10.3969/j.issn.1006-7795.2024.06.021

摘要/Abstract

摘要： 目的探讨血浆氧化三甲胺（trimethylamine N-oxide，TMAO）浓度与2型糖尿病（type 2 diabetes mellitus, T2DM）的关系。方法本研究选取2021年7月至2021年10月期间，在航天中心医院内分泌科住院的119例2型糖尿病患者和同期在本院进行健康体检的55例健康个体为研究对象。收集所有受试者的一般资料，采用酶联免疫吸附法测定血浆TMAO浓度，分析血浆TMAO浓度与T2DM的关系。结果 T2DM组患者的年龄、入院时的收缩压、舒张压、三酰甘油、空腹血糖、糖化血红蛋白均大于对照组，而血白蛋白、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇均低于对照组（P<0.05）；与对照组比较，T2DM患者血浆TMAO浓度明显升高［(137.83±11.80） pg/mL vs (122.65±10.93) pg/mL，P<0.05)］。Logistic回归分析显示，调整相关混杂因素后，年龄（OR=1.268，95%CI: 1.055~1.523，P =0.011）和血浆TMAO浓度（OR=1.186，95%CI: 1.005~1.399，P =0.043）是T2DM的危险因素，血浆TMAO浓度升高，T2DM的危险性增加。结论 T2DM患者表现出更高水平的血浆TMAO浓度，TMAO是T2DM的相关危险因素。

关键词: 氧化三甲胺, 2型糖尿病, 肠道菌群代谢产物

Abstract: Objective To investigate the association of plasma trimethylamine-N-oxide (TMAO) with type 2 diabetes mellitus (T2DM). Methods The total of 119 T2DM inpatients at the Department of Endocrinology, Aerospace Center Hospital from July 2021 to October 2021 were enrolled in the present study. The 55 healthy subjects who had physical examinations in Aerospace Center Hospital during the same period were also collected as the control group. General data of all subjects were recorded. Concentrations of plasma TMAO were measured by the enzyme-linked immunosorbent assay. The relationship between plasma TMAO and T2DM was analyzed. Results The patients with T2DM were older and had higher systolic blood pressure, diastolic blood pressure, triglyceride, fasting blood glucose and glycosylated hemoglobin.On the other side, serum albumin, high density lipoprotein-cholesterol, and low density lipoprotein-cholesterol were lower in the T2DM group than in the control group (P<0.05). As compared with the control group, the T2DM patients showed a significantly higher plasma TMAO ［(137.83±11.80) pg/mL vs (122.65±10.93) pg/mL, P<0.05)］. Logistic regression analysis found that age (OR=1.268, 95%CI: 1.055－1.523, P=0.011) and plasma TMAO concentration (OR=1.186, 95%CI: 1.005－1.399, P=0.043) were independently associated with T2DM after adjustment for confounding factors. Conclusions T2DM patients showed a higher plasma TMAO level, and T2DM was associated with plasma TMAO.

Key words: trimethylamine-N-oxide, type 2 diabetes mellitus, metabolites of intestinal flora

中图分类号:

R581.1

李晓静, 柳洪宙, 董松, 王鸿. 血浆氧化三甲胺浓度与2型糖尿病的关系[J]. 首都医科大学学报, 2024, 45(6): 1100-1105.

Li Xiaojing, Liu Hongzhou, Dong Song, Wang Hong. Association between plasma trimethylamine-N-oxide level and type 2 diabetes mellitus[J]. Journal of Capital Medical University, 2024, 45(6): 1100-1105.

参考文献

［1］中华医学会糖尿病学分会. 中国2型糖尿病防治指南（2017年版）［J］. 中华糖尿病杂志, 2018, 10(1): 4-67.
［2］ Tang W H, Kitai T, Hazen S L. Gut microbiota in cardiovascular health and disease［J］.Circ Res, 2017, 120(7): 1183-1196.
［3］ Croyal M, Saulnier P J, Aguesse A, et al. Plasma trimethylamine N-Oxide and risk of cardiovascular events in patients with type 2 diabetes［J］. J Clin Endocrinol Metab, 2020, 105(7): dgaa188.
［4］ Heianza Y, Sun D, Li X, et al. Gut microbiota metabolites, amino acid metabolites and improvements in insulin sensitivity and glucose metabolism: the POUNDS lost trial［J］. Gut, 2019, 68(2): 263-270.
［5］ Org E, Blum Y, Kasela S, et al. Relationships between gut microbiota, plasma metabolites, and metabolic syndrome traits in the METSIM cohort［J］. Genome Biol, 2017,18(1): 70.
［6］何倩, 杨建, 陈冰婷, 等. 基于16S rRNA测序对2型糖尿病患者肠道菌群特征的分析［J］. 新疆医科大学学报, 2022, 45 (11): 1262-1268.
［7］成彪,高凌云.氧化三甲胺与急性冠脉综合征的研究进展［J］.国际心血管病杂志, 2019, 46(4): 216-218.
［8］ Chen S, Henderson A, Petriello M C, et al. Trimethylamine-N-oxide binds and activates PERK to promote metabolic dysfunction［J］. Cell Metab, 2019, 30(6): 1141-1151.
［9］ Miao J, Ling A V, Manthena P V, et al. Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis［J］. Nat Commun, 2015, 6: 6498.
［10］ Gao X, Liu X, Xu J, et al. Dietary trimethylamine-N-oxide exacerbates impaired glucose tolerance in mice fed a high fat diet［J］. J Biosci Bioeng, 2014, 118(4): 476-481.
［11］ Dambrova M, Latkovskis G, Kuka J, et al. Diabetes is associated with higher trimethylamine-N-oxide plasma levels［J］. Exp Clin Endocrinol Diabetes, 2016, 124(4): 251-256.
［12］ Shan Z, Sun T, Huang H, et al. Association between microbiota-dependent metabolite trimethylamine-N-oxide and type 2 diabetes［J］. Am J Clin Nutr, 2017, 106(3): 888-894.
［13］ Tang W H W, Wang Z, Li X S, et al. Increased trimethylamine-N-oxide portends high mortality risk independent of glycemic control in patients with type 2 diabetes mellitus［J］. Clin Chem,2017, 63(1): 297-306.
［14］ Zhuang R, Ge X, Han L, et al. Gut microbe-generated metabolite trimethylamine N-oxide and the risk of diabetes: a systematic review and dose-response meta-analysis［J］. Obes Rev, 2019, 20(6): 883-894.
［15］ Papandreou C, Bulló M, Zheng Y, et al. Plasma trimethylamine-N-oxide and related metabolites are associated with type 2 diabetes risk in the Prevención con Dieta Mediterránea (PREDIMED) trial［J］. Am J Clin Nutr, 2018, 108(1): 163-173.
［16］ Lemaitre R N, Jensen P N, Wang Z, et al. Association of trimethylamine N-oxide and related metabolites in plasma and incident type 2 diabetes: the cardiovascular health study［J］. JAMA Network Open, 2021, 4(8): e2122844.
［17］ Alberti K G, Zimmet P Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation［J］. Diabet Med, 1998, 15(7): 539-553.
［18］ Mueller D M, Allenspach M, Othman A, et al. Plasma levels of trimethylamine-N-oxide are confounded by impaired kidney function and poor metabolic control［J］. Atherosclerosis, 2015, 243: 638-644.
［19］ Tang W H, Hazen S L. The contributory role of gut microbiota in cardiovascular disease［J］. J Clin Invest, 2014, 124: 4204-4211.
［20］ Bennett B J, Aguiar Vallim T Q, Wang Z, et al. Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation［J］. Cell Metab, 2013, 17: 49-60.
［21］ Shan Z, Chen S, Sun T, et al. U-shaped association between plasma manganese levels and type 2 diabetes［J］. Environ Health Perspect, 2016, 124: 1876-1881.
［22］ Gessner A, di Giuseppe R, Koch M, et al. Trimethylamine-N-oxide (TMAO) determined by LC-MS/MS: distribution and correlates in the population-based PopGen cohort［J］. Clin Chem Lab Med, 2020, 58(5): 733-740.
［23］王丹萍,徐珒昭,张晓航等. 糖尿病与宿主肠道菌群的关系及饮食介导的菌群调控作用研究进展［J］.食品科学, 2023, 44(15): 379－389.
［24］ Weifei Z, Kymberleigh A R, Lin L, et al.Gut microbes impact stroke severity via the trimethylamine N-oxide pathway［J］.Cell Host Microbe, 2021, 29(7): 1199－1208.
［25］ Svingen G F, Schartum-Hansen H, Pedersen E R, et al. Prospective associations of systemic and urinary choline metabolites with incident type 2 diabetes［J］. Clin Chem, 2016, 62: 755-765.
［26］ Lever M, George PM, Slow S, et al. Betaine and trimethylamine- N-oxide as predictors of cardiovascular outcomes show different patterns in diabetes mellitus: an observational study［J］. PLoS One, 2014, 9: e114969.
［27］ Winther S A, Øllgaard J C, Tofte N, et al. Utilty of plasma concentration of trimethylamine N-oxide in predicting cardiovascular and renal complications in individuals with type 1 diabetes［J］. Diabetes Care, 2019, 42(8): 1512-1520.
［28］ Xu J, Zhang J, Cai S, et al. Metabonomics studies of intact hepatic and renal cortical tissues from diabetic db/db mice using high-resolution magic-angle spinning 1H NMR spectroscopy［J］. Anal Bioanal Chem, 2009, 393(6-7): 1657-1668.
［29］ Lupachyk S, Watcho P, Stavniichuk R, et al. Endoplasmic reticulum stress plays a key role in the pathogenesis of diabetic peripheral neuropathy［J］. Diabetes, 2013, 62(3): 944-952.
［30］ Heianza Y, Sun D, Smith S R, et al. Changes in gut microbiota-related metabolites and long-term successful weight loss in response to weight-loss diets: the POUNDS lost trial［J］. Diabetes Care, 2018, 41(3): 413-419.
［31］ Winther S A, Øllgaard J C, Hansen T W, et al. Plasma trimethylamine N-oxide and its metabolic precursors and risk of mortality, cardiovascular and renal disease in individuals with type 2-diabetesand albuminuria［J］. PLoS One, 2021, 16(3): e0244402.
［32］ Tanase D M, Gosav E M, Neculae E, et al. Role of gut microbiota on onset and progression of microvascular complications of type 2 diabetes (T2DM)［J］. Nutrients, 2020, 12(12): 3719.
［33］ Croci S, D'Apolito L I, Gasperi V, et al. Dietary strategies for management of metabolic syndrome: role of gut microbiota metabolites［J］. Nutrients, 2021, 13(5): 1389.

[1]	李兴茂, 李秀, 王婷, 赵鑫, 王德杨, 商海燕, 赵咏梅, 李森. GLP-1 受体激动剂对 2 型糖尿病患者急性缺血性脑卒中后认知功能的影响[J]. 首都医科大学学报, 2024, 45(6): 1029-1037.
[2]	王恬园, 于芸, 韩如泉. 胰高血糖素样肽-1受体激动剂的临床应用及围术期研究进展[J]. 首都医科大学学报, 2024, 45(6): 1115-1121.